GlassScriptPhysician profile
John W Sistrunk
NPI 1164430419
$40,820.91
in general payments reported to CMS, 2019-2025
15 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $17K · 2021: $5,797 · 2022: $399 · 2023: $593 · 2024: $419 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $1,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,524.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23,590.21 | 2019-2022 | |
| Eli Lilly and Company | $7,387.50 | 2019-2020 | |
| Abbvie INC. | $4,142.33 | 2019-2025 | Ubrelvy, Synthroid |
| Ortho-Clinical Diagnostics, INC. | $2,400.00 | 2025 | Inflammadry |
| Quidel Corporation | $1,500.00 | 2021 | |
| Novo Nordisk INC | $437.86 | 2022-2025 | Wegovy |
| Amneal Pharmaceuticals LLC | $405.81 | 2020-2025 | Unithroid |
| Ascendis Pharma Endocrinology INC | $236.12 | 2023-2025 | Yorvipath |
| Corcept Therapeutics | $229.83 | 2019-2025 | Korlym |
| Eisai INC. | $123.56 | 2020 | |
| Lilly USA, LLC | $91.56 | 2022 | |
| Exelixis INC. | $87.32 | 2023 | Cabometyx |
| Amgen INC. | $80.42 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.78 | 2019 | |
| Ibsa Pharma INC. | $32.61 | 2023-2024 | Tirosint, Licart, Licart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sistrunk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.